CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D011111: Polymyalgia Rheumatica NIH

(Synonyms: Polymyalgia Rheumatica)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug532 COVID-19 Antibody testing Wiki 0.58
drug3320 life questionnaires Wiki 0.58
drug562 COVID-19 infection Wiki 0.58
drug3436 questionnaire Wiki 0.41
drug531 COVID-19 Wiki 0.41
drug870 Dexamethasone Wiki 0.24

Correlated MeSH Terms (14)


Name (Synonyms) Correlation
D013700 Giant Cell Arteritis NIH 1.00
D001167 Arteritis NIH 0.82
D025241 Spondylarthritis NIH 0.58
D008180 Lupus Erythematosus, Systemic NIH 0.47
D012859 Sjogren's Syndrome NIH 0.41
D008269 Macular Edema NIH 0.41
D001168 Arthritis NIH 0.32
D003095 Collagen Diseases NIH 0.29
D001327 Autoimmune Diseases NIH 0.29
D015535 Arthritis, Psoriatic NIH 0.29
D012216 Rheumatic Diseases NIH 0.24
D001172 Arthritis, Rheumatoid NIH 0.20
D009103 Multiple Sclerosis NIH 0.17
D002908 Chronic Disease NIH 0.17

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0012089 Arteritis HPO 0.82
HP:0002725 Systemic lupus erythematosus HPO 0.47
HP:0011505 Cystoid macular edema HPO 0.41
HP:0001369 Arthritis HPO 0.32
HP:0002960 Autoimmunity HPO 0.29
HP:0001370 Rheumatoid arthritis HPO 0.20

There are 3 clinical trials

Clinical Trials


1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747 Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Systemic Lupus Erythematosus Giant Cell Arteritis Other: COVID-19 infection
MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

Measure: Disease activity

Time: Last registration of disease activity in the medical journal before admission/inclusion

Secondary Outcomes

Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

Measure: Immune modulating treatments

Time: Current immune modulating treatments at admission/inclusion

Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

Measure: Biomarkers

Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1

2 COVID-19 Related Lockdown Effects On Chronic Diseases

The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.

NCT04390126 Chronic Coronary Syndrome Heart Failure AMD and Macular Edema Chronic Respiratory Failure Hemophilia Malignant Hemopathy Multiple Sclerosis Horton's Disease Other: life questionnaires Other: questionnaire
MeSH:Polymyalgia Rheumatica Respiratory Insufficiency Multiple Sclerosis Giant Cell Arteritis Macular Edema Chronic Disease
HPO:Cystoid macular edema Macular edema

Primary Outcomes

Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)

Measure: % adherence to each pharmacological class

Time: during the period from 20 April 2020 to 7 May 2020

Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)

Measure: number of occurrence of medical events at 1 year

Time: throughout the study for 12 months

Secondary Outcomes

Description: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change

Measure: Expressed in %: Non-pharmacological treatment/lifestyle:

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication

Time: during the period from 20 April 2020 to 7 May 2020

Measure: Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)

Time: during the period from 20 April 2020 to 7 May 2020

3 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

NCT04397237 COVID-19 Systemic Lupus Erythematosus Sjogren's Syndrome Axial Spondyloarthritis Rheumatoid Arthritis Giant Cell Arteritis
MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

Primary Outcomes

Description: ELISA tests for COVID-19 antibodies

Measure: COVID-19 seroconversion

Time: 1 day, during routine blood collection

Description: Case report form filled by the health professional

Measure: COVID-19 infection

Time: During medical visit or phone consultation, up to 2 hours

Secondary Outcomes

Description: Descriptive analysis for each disease's rate

Measure: Seroconversion rate by disease

Time: 1 day, during routine blood collection

Description: Descriptive analysis for each country's rate

Measure: Penetration across Europe

Time: 1 day, during routine blood collection

Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

Measure: COVID-19 severity

Time: During medical visit, up to 1 hour

Description: Descriptive analysis for overall and COVID-19-linked mortality rates

Measure: COVID-19 mortality rate

Time: During contact with family members, up to 1 hour

Description: Case report form filled by the health professional

Measure: COVID-19 impact on immunomodulatory treatment

Time: During medical visit, up to 1 hour

Description: Case report form filled by the patient

Measure: Patient-reported flares

Time: During medical visit, up to 1 hour

Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

Measure: Patient's fears towards COVID-19

Time: During medical visit, up to 1 hour

Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

Measure: Patient's beliefs in their medicines towards COVID-19

Time: During medical visit, up to 1 hour


HPO Nodes